Dead Space Evaluation in Pulmonary Hypertension

NCT02892981 | Completed

• 1 other identifier: ccm257
• Study Type: interventional
• Target: 18
• Locations: 0 countries
• Sites: N/A

Brief Summary

Aim of the study is to evaluate the role of chemoreceptor activity and ventilation perfusion mismatch on the genesis of exercise induced hyperventilation in Pulmonary hypertension patients. So the investigators tested the chemoreceptor response at rest, both with hypoxic and hypercapnic stimuli, and the ventilatory response during exercise analyzing its two components, alveolar and dead space ventilation.

Conditions

Pulmonary Hypertension

Outcome Measures

Primary Outcomes (1)

• dead space ventilation (measured in L/min)

  Dead space ventilation is calculated through the equation: VT\* \[1- (863\*VCO2)/(VE\*PaCO2)\], where VT = tidal volume, VCO2= CO2 output, VE= pulmonary ventilation,PaCO2 is the arterial partial pressure of CO2 and 863 is a constant.

  1 week

Secondary Outcomes (3)

• peripheral response to hypoxia (measured in L/min/O2)

  1 week

• peripheral response to hypercapnia (measured in L/min/mmHg)

  1 week

• central hypercapnic chemosensitivity (measured in L/min/mmHg)

  1 week

Study Arms (1)

Pulmonary hypertension patients

OTHER

All Pulmonary hypertension patients enrolled in the study underwent a cardiopulmonary exercise test and hypoxia and hypercapnia tests

Other: cardiopulmonary exercise test,hypoxia and hypercapnia test

Interventions

cardiopulmonary exercise test,hypoxia and hypercapnia test OTHER

class I and IV Pulmonary hypertension patients in stable haemodynamic status and optimized medical therapy underwent cardiopulmonary test and hypoxia and hypercapnia tests to evaluate the chemoreceptor sensitivity

Pulmonary hypertension patients

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• age ≥18 and ≤ 80 years
• ability to understand the research protocol and willing to sign the study informed consent
• diagnosis of pulmonary arterial hypertension belonging to Class I and IV
• stable haemodynamic status and optimized medical treatment since at least 2 months
• ability to perform maximal cardiopulmonary exercise test and pulmonary diffusing capacity for carbon monoxide evaluation

You may not qualify if:

• relevant comorbidities
• usual contraindications for cardiopulmonary exercise test
• pulmonary hypertension associated to left heart and pulmonary disease, congenital heart diseases with evident cardiac shunts.

Sponsors & Collaborators

• Centro Cardiologico Monzino: lead

Related Publications (1)

• Farina S, Bruno N, Agalbato C, Contini M, Cassandro R, Elia D, Harari S, Agostoni P. Physiological insights of exercise hyperventilation in arterial and chronic thromboembolic pulmonary hypertension. Int J Cardiol. 2018 May 15;259:178-182. doi: 10.1016/j.ijcard.2017.11.023.

  PMID: 29579597 DERIVED

MeSH Terms

Conditions

Hypertension, Pulmonary

Condition Hierarchy (Ancestors)

Lung Diseases; Respiratory Tract Diseases; Hypertension; Vascular Diseases; Cardiovascular Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: June 10, 2016
• First Posted: September 8, 2016
• Study Start: January 1, 2015
• Primary Completion: January 1, 2016
• Study Completion: April 1, 2016
• Last Updated: September 8, 2016

Record last verified: 2016-09